Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Fase 2, estudo aberto para avaliar a segurança e tolerabilidade da progerinina na síndrome de Werner

30 de setembro de 2026 atualizado por: PRG Science & Technology Co., Ltd.

Um estudo aberto de fase 2 para avaliar a segurança e tolerabilidade da progerinina para o tratamento da perda de densidade mineral óssea (BMD) em indivíduos com síndrome de Werner típica

This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.

There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Subjects who have successfully completed the Screening phase will enter the baseline and treatment phase of the study. Subjects will take the assigned treatment of Progerinin (2400 mg) split as 1200 mg BID in the morning and evening with food for 1-Year.

To evaluate the safety and tolerability of Progerinin for the treatment of BMD loss in subjects with typical Werner syndrome.

The secondary objectives of this study are:

  • To characterize the activity of Progerinin on bone metabolism in subjects with typical Werner Syndrome.
  • To evaluate vascular function in subjects with typical Werner Syndrome.
  • To evaluate glucose metabolism and insulin resistance in subjects with typical Werner Syndrome.
  • To evaluate lipid metabolism in subjects with typical Werner Syndrome.
  • To evaluate physical function in subjects with typical Werner Syndrome.
  • To evaluate the pharmacokinetics (PK) of Progerinin sachet administered twice daily (BID) in subjects with typical Werner Syndrome.

Tipo de estudo

Intervencional

Inscrição (Estimado)

5

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Recrutamento
        • University of Michigan

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

[Inclusion Criteria]

  1. Subjects must be at least ≥ 18 years of age.

  2. Subjects should have a confirmed diagnosis of typical Werner syndrome by genetic analysis.

  3. Subjects should be osteopenic (T-score between -1.0 and -2.5) or have confirmed osteoporosis (T-score ≤ -2.5) at screening/baseline. Subjects may continue to receive bone supplements (e.g., bisphosphonates, calcium supplements, Vitamin D supplements, etc.) as appropriate per standard of care throughout the study.

  4. Male or non-pregnant, non-lactating female.

  5. Subjects screening blood chemistry inclusive of metabolic panel, hematology, and urine analysis results should be acceptable to the investigator.

  6. Negative pregnancy test for female subjects as described below. Women of child bearing potential (WOCBP) and Women not of child-bearing potential are eligible to participate. Both women of childbearing potential and women of non-child-bearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study and for 90 days after last treatment.

    Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile or two years post-menopausal. All male subjects/partners must agree to use a In addition, subjects may not donate sperm for the duration of the study and for 90 days after last treatment.

    Females who are less than two (2) years post-menopausal, those with tubal ligations and those using contraception must have a negative serum pregnancy test at baseline within the one (1) week prior to the first study medication administration. Every six weeks, and at study termination a pregnancy test should be performed, either serum or urine stick test. However, if the urine result is positive, a serum pregnancy test will be performed.

  7. Provide signed written informed consent and willingness, ability to comply with study requirements.

  8. Subject must have a projected life expectancy of ≥ 12 months in the opinion of the Investigator.

[Exclusion Criteria]

  1. Subject with clinical signs seen at screening are at the final stage of Werner syndrome progression, and completion of the study is difficult to be assessed, including:

    • Subjects who received continuous or intermittent home oxygen therapy for 6 months before obtaining consent
    • Subjects who received at least 2 hospitalizations for pneumonia during the 12 months prior to obtaining consent
    • Subjects who have at least 10% net weight loss and have not recovered. This includes significant net weight loss over the last six months.
  2. Subjects with significant dehydration as judged by the principal investigator.

  3. Subjects with pericardial fluid, ascites and pleural effusion.

  4. Therapy with investigational drugs within 30 days of beginning study medication.

  5. History of prior malignancy, except for adequately treated in situ cancer, basal cell, squamous cell skin cancer, or other cancers (e.g., breast, prostate) for which the subject has been disease-free for at least 3 years.

  6. Any serious medical condition, laboratory abnormality, psychiatric illness, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for the study.

  7. Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous (IV) treatment for infection(s).

  8. Subjects with known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV).

  9. Subjects with a history of serious drug hypersensitivity or allergic reaction such as anaphylaxis or any component of the formulation.

  10. Clinically significant bleeding within 2 weeks prior to baseline (e.g., gastrointestinal [GI] bleeding, intracranial hemorrhage).

  11. Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit and for the duration of the trial.

  12. Pregnant or lactating women.

  13. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy), within 28 days prior to baseline or anticipated surgery during the study period.

  14. Inability to return for scheduled treatment and assessments.

  15. Subjects that require concomitant use of any medications or substances that are strong inhibitors or inducers of CYP2D6 or CYP2C8

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Treatment Group

all subjects will receive Progerinin 2400mg (1200mg twice daily) after morning and evening meals for a year

This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.

. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Prazo: Baseline to Week 56 (including 4-week follow-up)

The intensity of the event will be graded using CTCAE v6.0 criteria

Baseline to Week 56 (including 4-week follow-up)
Incidence of Treatment-Related Adverse Events
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Incidence of Serious Adverse Events (SAEs)
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Incidence of TEAEs and SAEs leading to discontinuation of study medication
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Blood Chemistry from Baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Hematology from Baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Urinalysis Results from Baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Height (cm) from Baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Weight (kg) from baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Temperature (°C) from baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Pulse Rate (beats per minute) from baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Respiratory Rate (breaths per minute) from baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Systolic Blood pressure (mmHg) from baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Diastolic Blood pressure (mmHg) from baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Physical Examination findings from baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG Ventricular Rate (beats per minute) from baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG PR interval (msec) from baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG QRS interval (msec) from baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG QT interval (msec) from baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG QTc interval (msec) from baseline
Prazo: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)

Medidas de resultados secundários

Medida de resultado
Prazo
Change in Femur Bone Mineral Density (BMD) from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Lumbar Spine BMD from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Aortic Pulse Wave Velocity (m/s) from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Insulin Resistance by Oral Glucose Tolerance Test (OGTT) from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Lipid Profile from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Handgrip Strength Test from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Short Physical Performance Battery (SPPB) Total Score from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Ankle-Brachial Pressure Index (ABPI) from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Bone-Specific Alkaline Phosphatase (BAP) from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Osteocalcin (OC) from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Procollagen Peptides (P1NP) from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Deoxypyridinium (DPD) from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in C-Terminal Telopeptide of Type 1 Collagen (CTX) from baseline
Prazo: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Pharmacokinetic Parameters of Progerinin at the Specified PK Assessment Visits
Prazo: Baseline, Week12, Week 24, Week 36 and Week 52
Baseline, Week12, Week 24, Week 36 and Week 52

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de outubro de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2027

Conclusão do estudo (Estimado)

1 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

31 de março de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de abril de 2023

Primeira postagem (Real)

6 de maio de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

30 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever